New COPD licence for Fostair

Fostair (formoterol/beclometasone) can now be prescribed for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Fostair (formoterol/beclometasone) delivers extra-fine particles allowing for a lower daily dose of corticosteroid
Fostair (formoterol/beclometasone) delivers extra-fine particles allowing for a lower daily dose of corticosteroid
The effect of formoterol/beclometasone on lung function and rate of exacerbation in patients with severe COPD (FEV1 30% to <50% predicted normal) was evaluated in two 48-week phase III studies.1

In the first, double-blind study (n=1186, analysis population), patients were randomised to receive formoterol/beclometasone (total daily dose 24/400 microgram) or formoterol alone (total daily dose 24 microgram).

A significant improvement in lung function (as assessed by change in pre-dose morning FEV1 from baseline to week 12) was observed for formoterol/beclometasone compared with formoterol alone (adjusted mean difference 0.07 [95% CI 0.04-0.10], p<0.001).2

Formoterol/beclometasone  also reduced the mean number of exacerbations per patient per year by 28% compared with formoterol alone (0.81 versus 1.11, adjusted rate ratio 0.72 [95% CI 0.62-0.84), p<0.001).2

In the second, three-arm parallel group study, 718 patients were randomised to receive treatment with formoterol/beclometasone metered dose inhaler (total daily dose 24/400 microgram), formoterol/budesonide dry powder inhaler (total daily dose 24/800 microgram) or formoterol dry powder inhaler (total daily dose 24 microgram).3

Formoterol/beclometasone was shown to be superior to formoterol alone (p=0.046) and non-inferior to formoterol/budesonide in terms of change in pre-dose morning FEV1 from baseline to 48 weeks.3

The mean rate of COPD exacerbations per patient per year was similar and did not differ significantly between the three treatment groups. All treatments were well tolerated.3

References
  1. .
  2. .
  3. .

View Fostair drug record

Further information: Chiesi Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New secondary prevention approach backed for patients with stable cardiovascular disease

New secondary prevention approach backed for patients with stable cardiovascular disease

NHS prescribers have a new routine option for preventing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...